Call to fund faecal calprotectin test

Thousands of patients with irritable bowel syndrome could avoid unnecessary colonoscopies if the MBS funded a simple stool test that can accurately rule out inflammatory bowel disease, gastroenterologists say.

The $80 point-of-care faecal calprotectin test accurately differentiates between IBD and IBS, but many gastroenterologists are still not using it because there is no MBS item for the test, according to a new study.